Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Background Ponatinib and blinatumomab are effective therapies in patients with
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with
hematologic malignancies; however, resistance and subsequent relapse remains a major …

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family,
discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in …